Tests sacituzumab tirumotecan to keep recurrent ovarian cancer controlled
Tests a drug, with or without bevacizumab, in adults with recurrent ovarian cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Key facts
- Where
- Calgary, Greater Sudbury, Mississauga, Montreal, and Toronto, CanadaSee the 6 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- Have your doctors told you that your cancer is advanced (stage 3 or 4)? This means it has spread beyond the ovaries to other parts of the belly or the body, even if it was later removed by surgery.
- What type of ovarian cancer do you have?
Source: NCT06824467, who can take part
Where in Canada
- Arthur J.E. Child Comprehensive Cancer Centre (Site 0512)Calgary, CanadaTaking people
- Health Sciences North Research Institute (Site 0517)Greater Sudbury, CanadaTaking people
- Trillium Health Partners - Credit Valley Hospital (Site 0508)Mississauga, CanadaTaking people
- CIUSSS de l'Est-de-l'Île-de-Montréal (Site 0505)Montreal, CanadaTaking people
- McGill University Health Centre (Site 0502)Montreal, CanadaTaking people
- Princess Margaret Cancer Centre (Site 0518)Toronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06824467EU 2023-508015-23-00
- Record updated
- 10 November 2026
- Original description
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.Read full original descriptionShow less
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Inclusion: Has locally advanced or metastatic, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies; Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line and a total of 6 to 8 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC); Has platinum-sensitive epithelial OC; Has provided tissue of a tumor lesion that was not previously irradiated; Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy; Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2); Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening; Has an ECOG performance status of 0 or 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2).
Exclusion: Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, or chronic diarrhea); Has received more than 2 prior lines of systemic therapy for OC; Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2); Has received prior radiotherapy within 2 weeks of allocation (Part 1) or randomization (Part 2), or has radiation related toxicities, requiring corticosteroids; Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), low-grade serous tumors, low-grade endometrioid tumors, borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma; Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing; Has uncontrolled, significant cardiovascular disease or cerebrovascular disease; Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected pneumonitis or ILD that cannot be ruled out by standard diagnostic assessments at Screening; HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Has an additional malignancy that is progressing or has required active treatment within the past 3 years; Has an active infection requiring systemic therapy; Has platinum-resistant OC or platinum-refractory OC; Has active central nervous system (CNS) metastases and/or carcinomatous meningitis; Has active or ongoing stomatitis.